Lawsuits Allege Ozempic Is Causing Blindness
Ozempic and similar weight loss drugs have been found to cut risks for a variety of health issues — ranging from heart to kidney disease — netting the pharma companies behind them billions of projected dollars in revenue over the next decade. But in rare cases, this class of drugs called GLP-1 agonists can come […]
GLP-1 pills are on the way. Here’s what to know : Short Wave – NPR
GLP-1 pills are on the way. Here’s what to know : Short Wave NPR Wegovy Maker Novo Nordisk Files for FDA Approval of Obesity Drug CagriSema The Wall Street Journal Eli Lilly, Novo Nordisk file new weight-loss drugs that could be game changers in obesity medicine MarketWatch Novo files marketing application for next-gen weight-loss drug Reuters Healthy Returns: 2026 […]
IJMS, Vol. 27, Pages 27: The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review
IJMS, Vol. 27, Pages 27: The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review International Journal of Molecular Sciences doi: 10.3390/ijms27010027 Authors: Dai Yamanouchi The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) play central roles in metabolic and cardiovascular regulation. GLP-1 receptor agonists (GLP-1RAs) are […]
Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity
Publication date: 20 December 2025–2 January 2026 Source: The Lancet, Volume 406, Issue 10522 Author(s): Edith Wing-Kar Chow, Elaine Chow
Maintenance, man: Lilly’s phase III weight trial hits goals
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase III Attain-Maintain trial with orforglipron, a once-daily oral small molecule GLP-1 receptor agonist. Indianapolis-based Lilly said that at one year orforglipron met the primary and all […]
Employers drop coverage for weight loss drugs as pharma’s direct-to-consumer programs grow – statnews.com
Employers drop coverage for weight loss drugs as pharma’s direct-to-consumer programs grow statnews.com Opinion | How to cut the velvet rope to GLP-1s The Washington Post Obesity recognition ‘going in right direction’ amid GLP-1 revolution, but obstacles remain thehill.com Covering the High Cost of Weight Loss Drugs National Conference of State Legislatures (NCSL) Study finds 40% of GLP-1 prescriptions […]
Eli Lilly’s Experimental Pill Could Help You Ditch GLP-1 Obesity Shots, Trial Finds
People who switched from semaglutide or tirzepatide to orforglipron largely maintained their weight loss.
Orforglipron Helps Maintain Weight Loss After Injectables
Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people maintain weight loss after switching from an injectable. Medscape Medical News
Eli Lilly is eyeing an off-ramp for patients to switch from weight loss injections to pills
Although the injectable forms of the popular GLP-1 drugs are more effective, the pills under development are both easier to take and will be cheaper
Can you get addicted to a GLP-1?
Model Brooks Nader calls these drugs a “crutch.”